These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20825223)

  • 1. Single-domain protein A-engineered magnetic nanoparticles: toward a universal strategy to site-specific labeling of antibodies for targeted detection of tumor cells.
    Mazzucchelli S; Colombo M; De Palma C; Salvadè A; Verderio P; Coghi MD; Clementi E; Tortora P; Corsi F; Prosperi D
    ACS Nano; 2010 Oct; 4(10):5693-702. PubMed ID: 20825223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy by immunoconjugated gold-gold sulfide nanoparticles using Protein G as a cofactor.
    Sun X; Zhang G; Patel D; Stephens D; Gobin AM
    Ann Biomed Eng; 2012 Oct; 40(10):2131-9. PubMed ID: 22532323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.
    Corsi F; Fiandra L; De Palma C; Colombo M; Mazzucchelli S; Verderio P; Allevi R; Tosoni A; Nebuloni M; Clementi E; Prosperi D
    ACS Nano; 2011 Aug; 5(8):6383-93. PubMed ID: 21790185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Steinhauser I; Spänkuch B; Strebhardt K; Langer K
    Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue.
    Eck W; Craig G; Sigdel A; Ritter G; Old LJ; Tang L; Brennan MF; Allen PJ; Mason MD
    ACS Nano; 2008 Nov; 2(11):2263-72. PubMed ID: 19206392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles.
    Occhipinti E; Verderio P; Natalello A; Galbiati E; Colombo M; Mazzucchelli S; Salvadè A; Tortora P; Doglia SM; Prosperi D
    Nanoscale; 2011 Feb; 3(2):387-90. PubMed ID: 20877896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging.
    Jun YW; Huh YM; Choi JS; Lee JH; Song HT; Kim S; Yoon S; Kim KS; Shin JS; Suh JS; Cheon J
    J Am Chem Soc; 2005 Apr; 127(16):5732-3. PubMed ID: 15839639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.
    Artemov D; Mori N; Okollie B; Bhujwalla ZM
    Magn Reson Med; 2003 Mar; 49(3):403-8. PubMed ID: 12594741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide.
    Jung Y; Kang HJ; Lee JM; Jung SO; Yun WS; Chung SJ; Chung BH
    Anal Biochem; 2008 Mar; 374(1):99-105. PubMed ID: 18023402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications.
    Iafisco M; Varoni E; Di Foggia M; Pietronave S; Fini M; Roveri N; Rimondini L; Prat M
    Colloids Surf B Biointerfaces; 2012 Feb; 90():1-7. PubMed ID: 22015181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatible functionalization of polymersome surfaces: a new approach to surface immobilization and cell targeting using polymersomes.
    Egli S; Nussbaumer MG; Balasubramanian V; Chami M; Bruns N; Palivan C; Meier W
    J Am Chem Soc; 2011 Mar; 133(12):4476-83. PubMed ID: 21370858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
    Sun B; Ranganathan B; Feng SS
    Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
    Spiridon CI; Guinn S; Vitetta ES
    Clin Cancer Res; 2004 May; 10(10):3542-51. PubMed ID: 15161714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody.
    Kocbek P; Obermajer N; Cegnar M; Kos J; Kristl J
    J Control Release; 2007 Jul; 120(1-2):18-26. PubMed ID: 17509712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.